“Impact of CardiolRx on Myocardial Recovery in patients with Acute Myocarditis. A double-blind, placebo-controlled trial (ARCHER)”

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-514639-10-00

Acronym

Cardiol 100-002

Enrollment

Registered

2024-07-09

Start date

2023-03-30

Completion date

2024-11-25

Last updated

2025-01-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Myocarditis

Brief summary

The primary outcome of this study is comprised of two primary endpoints; the difference in the means of each: extra cellular volume (ECV) and of global longitudinal strain (GLS), as measured by cardiac magnetic resonance (CMR) at 12 weeks post randomization between the active and the placebo groups.

Interventions

DRUGCardiolRx

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
The primary outcome of this study is comprised of two primary endpoints; the difference in the means of each: extra cellular volume (ECV) and of global longitudinal strain (GLS), as measured by cardiac magnetic resonance (CMR) at 12 weeks post randomization between the active and the placebo groups.	—

Countries

France

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026